Treatment with FXR agonists, GW4064, or INT-747, has been shown to reduce plasma triglyceride, glucose levels, and improve insulin sensitivity in several models of obesity and diabetes (Zhang et al., 2006; Mason et al., 2010). Here, INS is linked to obesity disorder.